{
  "issued_date": "2014-07-10", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON433919", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2014/027", 
    "Audience": "Healthcare professionals", 
    "Published": "10 July 2014 at 15:000", 
    "Format": "Electronic", 
    "Size": "A4", 
    "Pages": "4", 
    "Price": "Free", 
    "ISBN/ISSN": "None", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [], 
  "body": "## Device\n\nBreast implants. All types, makes and models.\n\n## Background\n\nAnaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin\u2019s lymphoma (NHL), a cancer involving the cells of the immune system. It accounts for less than 1% of all breast malignancies.\n\nIn January 2011, US Food and Drug Administration (FDA) published a safety communication entitled \u2018[FDA Medical Device Safety Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#summary)\u2019 (external link).\n\nIn a review by FDA of scientific literature published from January 1997 to May 2010, they identified 34 cases of ALCL in women with breast implants worldwide. FDA\u2019s adverse event reporting system also contained 17 reports of ALCL in women with breast implants.\n\nIn May 2014 the [final report on PIP silicone breast implants](http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_cons_14_en.htm) (external link) was published by the European Commission and its non-food Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) which identified 130 case reports worldwide of patients with all types of breast implants who had developed ALCL. This is a very small proportion of the 5-10 million women who have received breast implants worldwide.\n\nMHRA will analyse any further reports in order to build a fuller picture of the occurrence of this rare disease in association with breast implants.\n\n## Problem\n\nSince publishing MDA/2011/017 in February 2011 requesting healthcare professionals to report cases of anaplastic large cell lymphoma (ALCL) in women with breast implants we have received three reports of ALCL in the UK and more cases worldwide have been identified in the peer reviewed literature (see background).\n\nMHRA continues to collect and analyse information from UK healthcare professionals and other sources about this issue in order to build a fuller picture of the occurrence of this rare disease in association with breast implants.\n\nMHRA is issuing this alert to further encourage healthcare professionals to report cases of ALCL in women who have breast implants or who have had them removed.\n\n## Action\n\nNo change to current best practice is needed.\n\nThere is no indication for any routine action in the form of explantation or regular radiological or MRI examination\n\nIf you are contacted by concerned women about this issue, reassure them that ALCL is a rare form of cancer, which can be treated if detected in the early stages.\n\nAlways strongly encourage women to continue self-examination of their breasts and axillae (underarms) for any changes such as lumps, swelling or distortions and to consult their doctor if they have any concerns.\n\nWe urge you to report any confirmed cases of ALCL in women who have breast implants or who have had them removed to the [MHRA (in England and Wales)](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm) to [NIAIC (in Northern Ireland)](http://www.dhsspsni.gov.uk/index/hea/niaic/niaic_reporting_incidents.htm) (external link) or to [IRIC (in Scotland)](http://www.hfs.scot.nhs.uk/services/incident-reporting-and-investigation-centre-iric/how-to-report-an-adverse-incident/) (external link).\n\n### Action by  \n  \n  * Directors of surgical units involved in breast reconstruction and augmentation.  \n  * Medical directors.  \n  * Plastic surgeons and all surgeons involved in breast reconstruction and augmentation.  \n  * Nurse executive directors.  \n  * Specialist nurses involved in breast cancer care.  \n  * Radiation & medical oncology departments  \n  * General practitioners (for information only).  \n  \n## Distribution\n\nThis MDA has been sent to  \n  \n  * Care Quality Commission (CQC) (headquarters) for information  \n  * Clinical commissioning groups (CCGs)  \n  * HSC trusts in Northern Ireland (chief executives)  \n  * Local authorities in Scotland (equipment co-ordinators)  \n  * NHS boards and trusts in Wales (chief executives)  \n  * NHS boards in Scotland (equipment co-ordinators)  \n  * NHS England area teams for information  \n  * NHS trusts in England (chief executives)  \n  * Special health authorities for information  \n  \n### Onward distribution\n\nPlease bring this notice to the attention of relevant employees in your establishment. \u00a0\n\nBelow is a suggested list of recipients. \u00a0\n\nTrusts  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * Directors of surgical units involved in breast reconstruction or augmentation  \n  * Haematologists  \n  * Medical directors  \n  * Nursing executive directors  \n  * Plastic surgeons and all surgeons involved in breast reconstruction or augmentation  \n  * Radiation & medical oncology departments  \n  * Radiation oncologists  \n  * Radiation oncology, directors of  \n  * Radiology departments  \n  * Radiology directors  \n  * Specialist nurses involved in breast cancer care  \n  \n### Independent distribution\n\nEstablishments registered with the Care Quality Commission (CQC) (England only)\n\nThis alert should be read by:  \n  \n  * Breast augmentation centres  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \nPlease note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health\u2019s Central Alerting System (CAS) by sending an email to: [safetyalerts@dh.gsi.gov.uk](mailto:safetyalerts@dh.gsi.gov.uk) and requesting this facility.\n\n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert please email us at:\u00a0[dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2014/027 or 2011/002/002/291/003.\n\nTechnical aspects  \nMr Ian Smith or Mrs Sonal Vara  \nMedicines & Healthcare Products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ  \nTel: 020 3080 7306 / 7710  \nFax: 020 8754 3965  \nEmail: [ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk) or [sonal.vara@mhra.gsi.gov.uk](mailto:sonal.vara@mhra.gsi.gov.uk)\n\nClinical aspects  \nDr Camilla Fleetcroft  \nMedicines & Healthcare Products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ  \nTel: 020 3080 6097  \nFax: 020 8754 3965  \nEmail: [camilla.fleetcroft@mhra.gsi.gov.uk](mailto:camilla.fleetcroft@mhra.gsi.gov.uk)\n\n### How to report adverse incidents\n\nPlease report via our website:\u00a0[Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm)  \nFurther information about CAS can be found\u00a0[on the CAS website](https://www.cas.dh.gov.uk/Home.aspx)\u00a0(external link)\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system.\n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:\n\nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald BT4 3SQ\n\nTel: 02890 523 704  \nFax:\u00a002890 523 900\n\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm) (external link)\n\n### How to report adverse incidents in Northern Ireland\n\nPlease report directly to NIAIC, further information can be found on the\u00a0[NIAIC website](http://www.dhsspsni.gov.uk/niaic)\u00a0(external link)  \nFurther information about SABS can be found\u00a0[on the SABS website](http://sabs.dhsspsni.gov.uk/)\u00a0(external link)\n\n## Scotland\n\nAll requests regarding return, replacement or modification of the devices mentioned in this alert should be directed to the relevant supplier or manufacturer.\n\nOther enquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh EH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Incident Reporting and Investigation Centre](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/)\u00a0(external link)\n\n## Wales\n\nEnquiries in Wales should be addressed to:\n\nImproving Patient Safety Team  \nMedical Directorate  \nWelsh Government  \nCathays Park  \nCardiff CF10 3NQ\n\nEmail: [improvingpatientsafety@wales.gsi.gov.uk](mailto:improvingpatientsafety@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<span>Breast implants. All types, makes and models.</span>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Background</h2><div class=\"content_section\" id=\"Background\">\r\n\t\t\t\t\t\t\t\t<p>Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin&#8217;s lymphoma (NHL), a cancer involving the cells of the immune system. It accounts for less than 1% of all breast malignancies.</p>\n\n<p>In January 2011, US Food and Drug Administration (FDA) published a safety communication entitled &#8216;<a href=\"http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#summary\">FDA Medical Device Safety Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants</a>&#8217; (external link).</p>\n\n<p>In a review by FDA of scientific literature published from January 1997 to May 2010, they identified 34 cases of ALCL in women with breast implants worldwide. FDA&#8217;s adverse event reporting system also contained 17 reports of ALCL in women with breast implants.</p>\n\n<p>In May 2014 the <a href=\"http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_cons_14_en.htm\">final report on PIP silicone breast implants</a> (external link) was published by the European Commission and its non-food Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) which identified 130 case reports worldwide of patients with all types of breast implants who had developed ALCL. This is a very small proportion of the 5-10 million women who have received breast implants worldwide.</p>\n\n<p>MHRA will analyse any further reports in order to build a fuller picture of the occurrence of this rare disease in association with breast implants.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p>Since publishing MDA/2011/017 in February 2011 requesting healthcare professionals to report cases of anaplastic large cell lymphoma (ALCL) in women with breast implants we have received three reports of ALCL in the UK and more cases worldwide have been identified in the peer reviewed literature (see background).</p>\n\n<p>MHRA continues to collect and analyse information from UK healthcare professionals and other sources about this issue in order to build a fuller picture of the occurrence of this rare disease in association with breast implants.</p>\n\n<p>MHRA is issuing this alert to further encourage healthcare professionals to report cases of ALCL in women who have breast implants or who have had them removed.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<p>No change to current best practice is needed.</p>\n\n<p>There is no indication for any routine action in the form of explantation or regular radiological or MRI examination</p>\n\n<p>If you are contacted by concerned women about this issue, reassure them that ALCL is a rare form of cancer, which can be treated if detected in the early stages.</p>\n\n<p>Always strongly encourage women to continue self-examination of their breasts and axillae (underarms) for any changes such as lumps, swelling or distortions and to consult their doctor if they have any concerns.</p>\n\n<p>We urge you to report any confirmed cases of ALCL in women who have breast implants or who have had them removed to the <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\">MHRA (in England and Wales)</a> to <a href=\"http://www.dhsspsni.gov.uk/index/hea/niaic/niaic_reporting_incidents.htm\">NIAIC (in Northern Ireland)</a> (external link) or to <a href=\"http://www.hfs.scot.nhs.uk/services/incident-reporting-and-investigation-centre-iric/how-to-report-an-adverse-incident/\">IRIC (in Scotland)</a> (external link).</p>\n\n<h3>Action by</h3>\n\n<ul>\n<li>Directors of surgical units involved in breast reconstruction and augmentation.</li>\n\n<li>Medical directors.</li>\n\n<li>Plastic surgeons and all surgeons involved in breast reconstruction and augmentation.</li>\n\n<li>Nurse executive directors.</li>\n\n<li>Specialist nurses involved in breast cancer care.</li>\n\n<li>Radiation &amp; medical oncology departments</li>\n\n<li>General practitioners (for information only).</li>\n</ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been sent to</p>\n\n<ul>\n<li>Care Quality Commission (CQC) (headquarters) for information</li>\n\n<li>Clinical commissioning groups (CCGs)</li>\n\n<li>HSC trusts in Northern Ireland (chief executives)</li>\n\n<li>Local authorities in Scotland (equipment co-ordinators)</li>\n\n<li>NHS boards and trusts in Wales (chief executives)</li>\n\n<li>NHS boards in Scotland (equipment co-ordinators)</li>\n\n<li>NHS England area teams for information</li>\n\n<li>NHS trusts in England (chief executives)</li>\n\n<li>Special health authorities for information</li>\n</ul>\n\n<h3>Onward distribution</h3>\n\n<p>Please bring this notice to the attention of relevant employees in your establishment. &#160;</p>\n\n<p>Below is a suggested list of recipients. &#160;</p>\n\n<p><span>Trusts</span><br>\nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p>\n\n<ul>\n<li>Directors of surgical units involved in breast reconstruction or augmentation</li>\n\n<li>Haematologists</li>\n\n<li>Medical directors</li>\n\n<li>Nursing executive directors</li>\n\n<li>Plastic surgeons and all surgeons involved in breast reconstruction or augmentation</li>\n\n<li>Radiation &amp; medical oncology departments</li>\n\n<li>Radiation oncologists</li>\n\n<li>Radiation oncology, directors of</li>\n\n<li>Radiology departments</li>\n\n<li>Radiology directors</li>\n\n<li>Specialist nurses involved in breast cancer care</li>\n</ul>\n\n<h3>Independent distribution</h3>\n\n<p>Establishments registered with the Care Quality Commission (CQC) (England only)</p>\n\n<p>This alert should be read by:</p>\n\n<ul>\n<li>Breast augmentation centres</li>\n\n<li>Hospitals in the independent sector</li>\n\n<li>Independent treatment centres</li>\n\n<li>Private medical practitioners</li>\n</ul>\n\n<p><span>Please note: </span>CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health&#8217;s Central Alerting System (CAS) by sending an email to: <a href=\"mailto:safetyalerts@dh.gsi.gov.uk\">safetyalerts@dh.gsi.gov.uk</a> and requesting this facility.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\t<span style=\" color: rgb(85, 85, 85); font-family: arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none; background-color: rgb(255, 255, 255);\">If you have any comments or feedback on this Medical Device Alert please email us at:<span class=\"Apple-converted-space\">&#160;</span></span><a href=\"mailto:dts@mhra.gsi.gov.uk\" added=\"null\" style=\" color: rgb(10, 50, 150); text-decoration: underline; font-family: arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);\">dts@mhra.gsi.gov.uk</a>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2014/027 or 2011/002/002/291/003.</p>\n\n<p><span>Technical aspects</span><br>\nMr Ian Smith or Mrs Sonal Vara<br>\nMedicines &amp; Healthcare Products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ<br>\nTel: 020 3080 7306 / 7710<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:ian.smith@mhra.gsi.gov.uk\">ian.smith@mhra.gsi.gov.uk</a> or <a href=\"mailto:sonal.vara@mhra.gsi.gov.uk\">sonal.vara@mhra.gsi.gov.uk</a></p>\n\n<p><span>Clinical aspects</span><br>\nDr Camilla Fleetcroft<br>\nMedicines &amp; Healthcare Products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ<br>\nTel: 020 3080 6097<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:camilla.fleetcroft@mhra.gsi.gov.uk\">camilla.fleetcroft@mhra.gsi.gov.uk</a></p>\n\n<h3>How to report adverse incidents</h3>\n\n<p>Please report via our website:&#160;<a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\" added=\"null\">Reporting adverse incidents involving medical devices</a><br>\nFurther information about CAS can be found&#160;<a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\" added=\"null\">on the CAS website</a>&#160;(external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\t<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system.</p>\n\n<p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:</p>\n\n<p>Northern Ireland Adverse Incident Centre<br>\nHealth Estates Investment Group<br>\nRoom 17<br>\nAnnex 6<br>\nCastle Buildings<br>\nStormont Estate<br>\nDundonald BT4 3SQ</p>\n\n<p>Tel: 02890 523 704<br>\nFax:&#160;02890 523 900</p>\n\n<p>Email: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\">NIAIC@dhsspsni.gov.uk</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\">Northern Ireland Adverse Incident Centre (NIAIC)</a> (external link)</p>\n\n<h3>How to report adverse incidents in Northern Ireland</h3>\n\n<p>Please report directly to NIAIC, further information can be found on the&#160;<a href=\"http://www.dhsspsni.gov.uk/niaic\" added=\"null\">NIAIC website</a>&#160;(external link)<br>\nFurther information about SABS can be found&#160;<a href=\"http://sabs.dhsspsni.gov.uk/\" added=\"null\">on the SABS website</a>&#160;(external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>All requests regarding return, replacement or modification of the devices mentioned in this alert should be directed to the relevant supplier or manufacturer.</p>\n\n<p>Other enquiries and adverse incident reports in Scotland should be addressed to:</p>\n\n<p>Incident Reporting and Investigation Centre<br>\nNHS National Services Scotland<br>\nGyle Square<br>\n1 South Gyle Crescent<br>\nEdinburgh EH12 9EB</p>\n\n<p>Tel: 0131 275 7575<br>\nFax: 0131 314 0722</p>\n\n<p>Email: <a href=\"mailto:nss.iric@nhs.net\">nss.iric@nhs.net</a></p>\n\n<p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\" added=\"null\">Incident Reporting and Investigation Centre</a>&#160;(external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:</p>\n\n<p>Improving Patient Safety Team<br>\nMedical Directorate<br>\nWelsh Government<br>\nCathays Park<br>\nCardiff CF10 3NQ</p>\n\n<p>Email: <a href=\"mailto:improvingpatientsafety@wales.gsi.gov.uk\">improvingpatientsafety@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: Breast implants. All types, makes and models (MDA/2014/027)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": [
    "cosmetic-surgery", 
    "general-practice", 
    "general-surgery", 
    "haematology-oncology"
  ]
}